18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer

PurposeQuantification of tumour heterogeneity in PET images has recently gained interest, but has been shown to be dependent on image reconstruction. This study aimed to evaluate the impact of the EANM/EARL accreditation program on selected 18F-FDG heterogeneity metrics.MethodsTo carry out our study, we prospectively analysed 71 tumours in 60 biopsy-proven lung cancer patient acquisitions reconstructed with unfiltered point spread function (PSF) positron emission tomography (PET) images (optimised for diagnostic purposes), PSF-reconstructed images with a 7-mm Gaussian filter (PSF7) chosen to meet European Association of Nuclear Medicine (EANM) 1.0 harmonising standards, and EANM Research Ltd. (EARL)-compliant ordered subset expectation maximisation (OSEM) images. Delineation was performed with fuzzy locally adaptive Bayesian (FLAB) algorithm on PSF images and reported on PSF7 and OSEM ones, and with a 50 % standardised uptake values (SUV)max threshold (SUVmax50%) applied independently to each image. Robust and repeatable heterogeneity metrics including 1st-order [area under the curve of the cumulative histogram (CHAUC)], 2nd-order (entropy, correlation, and dissimilarity), and 3rd-order [high-intensity larger area emphasis (HILAE) and zone percentage (ZP)] textural features (TF) were statistically compared.ResultsVolumes obtained with SUVmax50% were significantly smaller than FLAB-derived ones, and were significantly smaller in PSF images compared to OSEM and PSF7 images. PSF-reconstructed images showed significantly higher SUVmax and SUVmean values, as well as heterogeneity for CHAUC, dissimilarity, correlation, and HILAE, and a wider range of heterogeneity values than OSEM images for most of the metrics considered, especially when analysing larger tumours. Histological subtypes had no impact on TF distribution. No significant difference was observed between any of the considered metrics (SUV or heterogeneity features) that we extracted from OSEM and PSF7 reconstructions. Furthermore, the distributions of TF for OSEM and PSF7 reconstructions according to tumour volumes were similar for all ranges of volumes.ConclusionPSF reconstruction with Gaussian filtering chosen to meet harmonising standards resulted in similar SUV values and heterogeneity information as compared to OSEM images, which validates its use within the harmonisation strategy context. However, unfiltered PSF-reconstructed images also showed higher heterogeneity according to some metrics, as well as a wider range of heterogeneity values than OSEM images for most of the metrics considered, especially when analysing larger tumours. This suggests that, whenever available, unfiltered PSF images should also be exploited to obtain the most discriminative quantitative heterogeneity features.

[1]  Ronald Boellaard,et al.  Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation , 2016, Molecular Imaging and Biology.

[2]  F. Gleeson,et al.  Phantom and Clinical Evaluation of the Bayesian Penalized Likelihood Reconstruction Algorithm Q.Clear on an LYSO PET/CT System , 2015, The Journal of Nuclear Medicine.

[3]  M. Hatt,et al.  Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.

[4]  R. Boellaard Methodological aspects of multicenter studies with quantitative PET. , 2011, Methods in molecular biology.

[5]  Dong Soo Lee,et al.  Autoclustering of Non-small Cell Lung Carcinoma Subtypes on 18F-FDG PET Using Texture Analysis: A Preliminary Result , 2014, Nuclear Medicine and Molecular Imaging.

[6]  P. Christian,et al.  PET/CT scanner validation for clinical trials-reasons for failure, recipes for success: the Clinical Trials Network (CTN) experience. , 2015 .

[7]  Sébastien Jodogne,et al.  FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Osama Mawlawi,et al.  Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors. , 2016, Radiology.

[9]  M. Lozano,et al.  Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Y. D'Asseler,et al.  Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  C. Chu,et al.  Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  M. Hatt,et al.  18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort , 2015, The Journal of Nuclear Medicine.

[13]  Ronald Boellaard,et al.  Mutatis Mutandis: Harmonize the Standard! , 2012, The Journal of Nuclear Medicine.

[14]  Bernd J. Pichler,et al.  Image-derived biomarkers and multimodal imaging strategies for lung cancer management , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Zhi-pei Liang,et al.  Introduction to biomedical imaging , 2008 .

[16]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Dimitris Visvikis,et al.  Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements , 2010, The Journal of Nuclear Medicine.

[18]  Christian Roux,et al.  A Fuzzy Locally Adaptive Bayesian Segmentation Approach for Volume Determination in PET , 2009, IEEE Transactions on Medical Imaging.

[19]  P. Christian,et al.  Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom , 2015, The Journal of Nuclear Medicine.

[20]  Pierre Vera,et al.  FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2) , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Florent Tixier,et al.  The age of reason for FDG PET image-derived indices , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Ronald Boellaard,et al.  Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  M. Hatt,et al.  Do clinical , histological or immunohistochemical primary tumor characteristics translate into different 18 FDG-PET / CT volumetric and heterogeneity features in stage II-III breast cancer ? , 2015 .

[24]  Issam El-Naqa,et al.  Exploring feature-based approaches in PET images for predicting cancer treatment outcomes , 2009, Pattern Recognit..

[25]  Nicolas Aide,et al.  Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Dimitris Visvikis,et al.  Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  R. Boellaard Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[28]  R. Jeraj,et al.  Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters , 2010, Acta oncologica.

[29]  Dimitris Visvikis,et al.  PET functional volume delineation: a robustness and repeatability study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Dimitris Visvikis,et al.  Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. , 2010, International journal of radiation oncology, biology, physics.

[31]  D. Townsend,et al.  Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET , 2015, The Journal of Nuclear Medicine.

[32]  R. Modzelewski,et al.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  D. Binns,et al.  Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  S. Swisher,et al.  Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  C. Chung Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[36]  N. Aide,et al.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  Fei Yang,et al.  Quantitative radiomics: impact of stochastic effects on textural feature analysis implies the need for standards , 2015, Journal of medical imaging.

[38]  Paul Kinahan,et al.  Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  Vladimir Y. Panin,et al.  Fully 3-D PET reconstruction with system matrix derived from point source measurements , 2006, IEEE Transactions on Medical Imaging.

[40]  M. Hatt,et al.  Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  Thomas Beyer,et al.  High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  El Naqa,et al.  A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities , 2015 .